RIPK1 inhibitor - Pipeline Insights, 2024

This “RIPK1 inhibitors - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in RIPK1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

RIPK1 inhibitors Understanding

RIPK1 inhibitors: Overview

The receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a crucial signaling protein involved in a broad range of inflammatory processes and is a key mediator of regulated cell death. The family of RIPKs comprises seven members, classified as dual-specificity kinases targeting both tyrosine as well as serine/threonine residues in their substrates. RIPK1 kinase activity is effective in a variety of human diseases. Initially, RIPK1 inhibitors were considered as small molecule alternatives to anti-TNF antibody therapy, primarily in TNF-driven autoimmune diseases. It is a 76-kDa protein with an amino-terminal (N-terminal) kinase domain, a carboxy-terminal (C-terminal) death domain, and an intermediate domain with an RHIM (receptor-interacting protein homotypic interacting motif), which is highly homologous to RIPK3 and can bind to other RHIM-containing proteins. Whereas the C-terminal death domain mediates homodimerization as well as heterodimerization with other death domain-containing proteins, such as FADD, TNFR1, and Fas, the N-terminal kinase domain mediates autophosphorylation in trans to promote its activation. The identification of RIPK1 kinase as an important mediator of both cell death and inflammation offers exciting new opportunities for the development of therapies to treat human diseases. RIPK1 inhibitors are also expected to be effective in the treatment of human peripheral inflammatory diseases and autoimmune disorders, but the ability to develop highly specific RIPK1 inhibitors that can cross the blood-brain barrier (BBB) in CNS also offers a unique opportunity to treat the related diseases.

RIPK1 inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the RIPK1 inhibitors pipeline landscape is provided which includes the disease overview and RIPK1 inhibitors treatment guidelines. The assessment part of the report embraces, in depth RIPK1 inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, RIPK1 inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence RIPK1 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve RIPK1 inhibitors.

RIPK1 inhibitors Emerging Drugs Chapters

This segment of the RIPK1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

RIPK1 inhibitors Emerging Drugs

SAR443122: Sanofi SAR443122 (DNL758) is a small molecule inhibitor of a protein known as RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which is involved in the tumor necrosis factor (TNF) receptor pathway that is implicated in inflammation, immunity, and cell death. RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. Sanofi has successfully completed the Phase I study with peripherally-restricted RIPK1 inhibitor DNL758(c) to treat SARS-CoV-2 viral infection and conducting Phase II clinical trial to treat Cutaneous Lupus Erythematosus. Furthermore, Sanofi plans to initiate a Phase II trial of SAR443122 in patients with ulcerativecolitis.

GFH312: Gen Fleet Therapeutics GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF-a downstream. GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage. Preclinical data of GFH312 have demonstrated its effects in suppressing inflammation (peripheral and neuronal), reducing pathological as well as behavioral deficits, and improving survival in animal models with acute systemic inflammation resulting from multiple tissue injury. GFH312 effectively inhibit the activity of RIPK1, and the Phase I trial will explore its safe dose range and tolerability in healthy subjects providing basis for further clinicaldevelopment.

R552: Rigel Pharmaceuticals R552, the drug is supposed to block an enzyme that plays a role in a wide range of cellular processes, including inflammation and cell death. Eli Lilly and Rigel Pharmaceuticals have collaborated to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 or RIPK1 inhibitor, for the potential treatment of immunological and neurodegenerative diseases. Rigel's lead RIPK1 inhibitor, R552, has completed Phase I clinical trials and the planning to begin Phase II clinical trials is underway as part of the collaboration.

RIPK1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different RIPK1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in RIPK1 inhibitors

There are approx. 10+ key companies which are developing the therapies for RIPK1 inhibitors. The companies which have their RIPK1 inhibitors drug candidates in the most advanced stage, i.e. Phase II include Sanofi.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

RIPK1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

RIPK1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RIPK1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RIPK1 inhibitors drugs.

RIPK1 inhibitors Report Insights

• RIPK1 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

RIPK1 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing RIPK1 inhibitors drugs?
• How many RIPK1 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of RIPK1 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the RIPK1 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for RIPK1 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.